These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14984635)

  • 21. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.
    Bennett CL; Weinberg PD; Rozenberg-Ben-Dror K; Yarnold PR; Kwaan HC; Green D
    Ann Intern Med; 1998 Apr; 128(7):541-4. PubMed ID: 9518398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 23. A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
    Shapiro M; Ward KM; Stern JJ
    AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombotic thrombocytopenic purpura associated with ticlopidine.
    Türken O; Oztürk A; Orhan B; Kandemir G; Yaylaci M
    Acta Haematol; 2003; 109(1):40-2. PubMed ID: 12486322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombotic thrombocytopenic purpura in autoimmune hepatitis.
    Shibuya A; Satomich A; Nagaba S; Endoh H; Kuwao S; Saigenji K
    J Gastroenterol; 2001 Aug; 36(8):569-73. PubMed ID: 11519838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.
    Dabak V; Kuriakose P; Raman S
    J Clin Apher; 2007; 22(6):330-2. PubMed ID: 18080270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
    Martin A; Amin J; Cooper DA; Carr A; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S;
    AIDS; 2010 Nov; 24(17):2657-63. PubMed ID: 20827168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
    Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O
    Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Brothers C; Cutrell A; Scott T; Hernandez J; Moult A
    Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic thrombocytopenic purpura in a 15-year-old female.
    Dakowicz L; Krawczuk-Rybak M
    Klin Padiatr; 2013 Nov; 225(6):362-3. PubMed ID: 23519752
    [No Abstract]   [Full Text] [Related]  

  • 33. [Use of plasmapheresis in the treatment of thrombotic thrombocytopenic purpura].
    Sułek K; Ostrowska G
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):887-8, 901. PubMed ID: 2487944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmapheresis with exchange as primary treatment for thrombotic thrombocytopenic purpura.
    Dayoan ES; Dixon AC; Rizzo E; Nakamura JM
    Hawaii Med J; 1990 Feb; 49(2):44, 46, 49-51. PubMed ID: 2332332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.
    Degen O; van Lunzen J; Stellbrink HJ
    Antivir Ther; 2000 Jun; 5(2):91-4. PubMed ID: 10971861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
    Gallant JE; Parish MA; Keruly JC; Moore RD
    Clin Infect Dis; 2005 Apr; 40(8):1194-8. PubMed ID: 15791522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HIV agents. Controversial findings on abacavir and heart attacks.
    TreatmentUpdate; 2008 Mar; 20(2):1-5. PubMed ID: 18661643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.